Metabolism and excretion of semaglutide, a GLP-1 analogue, in humans and nonclinical species
Additional metabolic conditions linked to cataract formation include Fabry's disease, Lowe's syndrome, Hurler's syndrome, and neonatal hypoglycemia
However, global health authorities including the World Health Organization (WHO) and United States Food and Drug Administration (US FDA) have cautioned against the use of unregulated and compounded weight-loss injections, highlighting concerns over safety, quality, and lack of oversight
Discussing this with biotech/pharma sponsors and building some dose escalation buffer into a protocol to keep the participant in the study and manage these AEs (when possible) can be a good strategy to keep participants in the trial & improve their experience
Notes: Not suitable for children or teens